

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER  
THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2019  
Commission File Number 001-38370

**CollPlant Biotechnologies Ltd.**  
(Exact name of registrant as specified in its charter)

**4 Oppenheimer, Weizmann Science Park**  
**Rehovot 7670104, Israel**  
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐

The first sentence of the first paragraph and "Forward Looking Statements" of the press release attached to this Form 6-K are hereby incorporated by reference into the registrant's Registration Statements on Form S-8 (File No. [333-229163](#)) and Form F-3 (File No. [333-229486](#) and [333-228054](#)), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

---

---

CollPlant Biotechnologies Ltd. (the “Company”) has posted to its website an updated corporate presentation. A copy of the presentation is furnished with this Report of Foreign Private Issuer on Form 6-K as [Exhibit 99.1](#) and is incorporated herein by reference.

Attached hereto as [Exhibit 99.2](#) and incorporated by reference herein is a press release issued by the Company entitled “CollPlant Biotechnologies Closes on \$5.5 Million Financing.”

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**COLLPLANT BIOTECHNOLOGIES LTD.**

Date: September 9, 2019

By: /s/ Eran Rotem

Name: Eran Rotem

Title: Deputy CEO and Chief Financial Officer



## CollPlant Overview

**CollPlant**  
Biotechnologies | Pioneering  
Regenerative  
Medicine

September 2019

---

# Safe Harbor Statement

Certain statements in this presentation constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "will," and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control. Risks and uncertainties for our company include, but are not limited to: the Company's history of significant losses, its ability to continue as a going concern, and its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all; the Company's expectations regarding the timing and cost of commencing clinical trials with respect to tissues and organs which are based on its rhCollagen based BioInk, dermal fillers for aesthetics, breast implants, VergenixSTR, and VergenixFG; the Company's ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen based BioInk, dermal fillers for aesthetics, breast implants, VergenixSTR, and VergenixFG including but not limited to acceptance of an application for marketing authorization, review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based BioInk, dermal fillers for aesthetics, VergenixSTR, and VergenixFG; the Company's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the Company's reliance on third parties to conduct some or all aspects of its product manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company's ability to operate its business without infringing the intellectual property rights of others; the overall global economic environment; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates; projected

capital expenditures and liquidity; changes in the Company's strategy; and litigation and regulatory proceedings. Many of these factors that will determine actual results are beyond our ability to control or predict. For a discussion of the factors that may cause our actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied in such forward-looking statements, see the "Risk Factors" section of included in our most recently filed Annual Report on Form 20-F. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

The statements made in this presentation speak only as of the date stated herein, and subsequent events and developments may cause our expectations and beliefs to change. Unless otherwise required by applicable securities laws, we do not intend, nor do we undertake any obligation, to update or revise any forward-looking statements contained in this presentation to reflect subsequent information, events, results or circumstances or otherwise. While we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise, except as required by law.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of such products.

## Overview

- Deep Tech\* company developing, manufacturing and commercializing regenerative medicine products
- Proprietary technology platform that enables mass production of recombinant human collagen (rhCollagen)
- rhCollagen-based products aimed at 3D Bioprinting of tissues and organs, and medical aesthetics markets
- Strategic agreement with United Therapeutics (NASDAQ: UTHR) for 3D bioprinting of lung transplants and other life saving organs

\* Deep Technologies are novel technologies that offer significant advances over those currently in use.

(Source: The Dawn of the Deep Tech Ecosystem, BCG, March 2019)

3



---

## Experienced management team



**Prof. Oded Shoseyov**  
**Co-Founder & Chief Scientist**

Pauli Clean Tech  
CBD Tech.  
Fulcrum-SPD  
Melodea  
Hebrew University



**Yehiel Tal**  
**CEO**

Regentis Biomaterials  
ProChon Biotech  
Kulicke & Soffa Industries



**Eran Rotem**  
**Deputy CEO & CFO**

Tefron, CFO (NYSE, TASE)  
Healthcare Tech., CFO  
(NASDAQ) & Gamida  
E&Y



**Nadav Orr, PhD**  
**VP R&D**

Ethicon Biosurgery,  
Johnson & Johnson



**Ilana Belzer, PhD**  
**COO**

BioHarvest  
Procognia Ltd.  
Omrix Biopharmaceuticals  
Interpharm




**Philippe Bensimon, PharmD**  
**VP RA/QA/CA**

Maquet Getinge  
3M Medical

# CollPlant's technology

Co-expression of 5 human genes in tobacco plants for the production of functional type I human recombinant Collagen





# Plant-derived rhCollagen

The ideal building block for regenerative medicine

## Clear advantages over animal-derived collagen



### Better bio-functionality

- Accelerates human cell proliferation
- Faster tissue healing



### Superior homogeneity

- Controlled physical/rheological properties
- Reproducibility
- Transparency (not visible)




### Improved safety and greater purity

- Non-immunogenic
- Non-allergenic
- No pathogens
- No foreign body response

6

#### Animal- derived




Few cell binding domains due to partially denatured crosslinked collagen




Slow cell proliferation and slow tissue repair Foreign body reactions (e.g. granuloma)

#### Plant-derived



Many cell binding domains enabled by perfect triple helix enhance cellular attachment



Fast cell proliferation and fast tissue repair

# Medical aesthetics

## Regenerative dermal filler



## Dermal fillers market overview



~2,091,476 HA procedures in 2017 in the US<sup>1</sup>




Global dermal filler market, 2017<sup>2</sup>



Cost per syringe: \$100-\$250/unit<sup>3</sup>

8

2017 Procedure breakdown, U.S (by material)\*



<sup>1</sup><https://www.plasticsurgery.org/documents/News/Statistics/2017/plastic-surgery-statistics-report-2017.pdf>

<sup>2</sup><https://www.gminsights.com/industry-analysis/dermal-filler-market>

<sup>3</sup><https://www.medicalsparex.com/juvederm-hydrate> , <https://www.medicalsparex.com/buy-juvederm-ultra-plus-xc>

# Combining the advantages of Collagen and Hyaluronic Acid

## HA

### Physical properties

- Highly viscous:  
Provides mechanical stability after injection
- Convenient injection:  
37-32G needle, 10-15N expression force
- High lifting capacity
- Transparent

The  
best of  
both  
worlds

## rhCollagen

### Biological properties

- Promotes cell adhesion and proliferation
- Promotes tissue regeneration
- Non allergic/non immunogenic

# Photocurable rhCollagen-HA regenerative dermal filler



Easy injection  
(30G needle)



Sculpturing before  
curing



Optimized post  
curing stiffness



Good tissue  
retention


## Injection



## Sculpturing



## Photocuring in-situ



# 3D Bioprinting

tissues & organs





## Organ transplantations are expensive and inefficient

Average transplant costs and wait times in USA:



**HEART** (2,725/YEAR)

\$1.4 million  
191 days



**KIDNEY** (16,804/YEAR)

\$415,000  
679 days



**LUNGS** (1,397/YEAR)

\$1.2 million  
185 days



**PANCREAS** (136/YEAR)

\$347,000  
281 days



**LIVER** (6,158/YEAR)

\$813,000  
239 days



**CORNEA** (50,099/YEAR)

\$30,200  
50 days

The advent of 3D bioprinting is expected to enable **unlimited, economical access to organs around the world**

<http://us.milliman.com/uploadedFiles/insight/2017/2017-Transplant-Report.pdf>  
U.S. Department of Health & Human Services

<https://optn.transplant.hrsa.gov/data/>

Lewis JK, Bischof JC, Braslavsky I, Brockbank K, Fahy G, Fuller B, Rabin Y, Tocchio A, Woods E, Wowk B, Acker J and Giwa S; The Grand Challenges of Organ Banking: Proceedings from the first global summit on complex tissue cryopreservation, Cryobiology, Volume 72, April 2016, Pages 169-182.

**~30,000**

US transplants per  
year

**115,000**

US waiting list

**900,000**

US deaths per year  
from organ impairment



## 3D bioprinting major market segments



### Organs

- Lungs
- Liver
- Kidney
- Heart



### Endocrine glands

- Ovary
- Pancreas
- Thyroid



### Tissues

- Skin
- Cornea
- Bones
- Cartilage
- Breast
- Heart valves



### Scaffolds

- Spine fusion
- Non-union fractures
- Craniomaxillofacial
- Nerve conduits
- Tendons & ligaments

#### ORGANS

900,000 patients<sup>1</sup>

#### OVARY

700,000 patients<sup>2</sup>

#### BREAST

500,000 patients<sup>3</sup>

#### SPINE FUSION

400,000 patients<sup>4</sup>


<sup>1</sup>In the U.S, total number- Lewis JK, Bischof JC, Braslavsky I, Brockbank K, Fahy G, Fuller B, Rabin Y, Tocchio A, Woods E, Wowk B, Acker J and Giwa S; The Grand Challenges of Organ Banking: Proceedings from the first global summit on complex tissue cryopreservation, Cryobiology, Volume 72, April 2016, Pages 169-182.

<sup>2</sup><https://www.womenshealth.gov/menopause/early-or-premature-menopause> <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3634232/>

<sup>3</sup><https://www.plasticsurgery.org/documents/News/Statistics/2018/plastic-surgery-statistics-full-report-2018.pdf>- Breast augmentation, lift and reconstruction

<sup>4</sup>In the U.S, annually, <https://www.ors.org/Transactions/57/0642.pdf>





## BioInk for 3D printing of tissues and organs

CollPlant's rhCollagen-based BioInk offers ideal characteristics for 3D bioprinting



Optimal rheology at room temperature - Viscosity and gelation kinetics



Biocompatible – supports viability of different cell types




Non immunogenic, excellent safety profile in clinical use (rhCollagen)



Tunable physical and mechanical properties

---

## Collaboration agreement with United Therapeutics (Oct. 2018)





- Global licensing and commercialization agreement for 3D Bioprinting of solid organ scaffolds for human transplants
- Collaboration combines CollPlant's proprietary BioInk technology and United Therapeutics' regenerative medicine and organ manufacturing capabilities

### Agreement highlights:


- \$5M upfront payment
- Up to \$39M milestone and option payments
- Royalties on product sales
- United Therapeutics has the option to expand the license to add up to three organs
- United Therapeutics will establish a U.S. facility for the manufacture of CollPlant's rhCollagen and BioInk

## 3D bioprinting of trachea and bronchi



100μ perfused vessels

# Breast implants



## Breast implants market overview

Current breast reconstruction is based on synthetic breast implantation, free flap surgery/autologous fat tissue transfer - all of which replace tissue rather than regenerate it



### Market

**\$1.4B**


worldwide (2018)<sup>1</sup>



### Cost

**\$ 5-10K**

per procedure in US<sup>2</sup>



### Procedure\*

- Breast augmentation
- Breast lift
- Breast reconstruction<sup>3</sup>

\* US segmentation



**~2,500,000**

Breast implant procedures WW (2017)<sup>4</sup>

**~500,000** in US (2018)<sup>5</sup>



### FDA alert:


Patients with breast implants have an increased risk of developing breast implant Associated- Anaplastic Large Cell Lymphoma (Feb 2019)<sup>6</sup>

1. Analytical Research Cognizance, Global Breast Implant Market, March 2019  
2. <https://www.webmd.com/beauty/cosmetic-procedures-breast-augmentation#1>  
3. [www.plasticsurgery.org/documents/News/Statistics/2018/plastic-surgery-statistics-full-report-2018.pdf](http://www.plasticsurgery.org/documents/News/Statistics/2018/plastic-surgery-statistics-full-report-2018.pdf)  
4. Breast augmentation and breast lift - [https://www.isaps.org/wp-content/uploads/2018/10/ISAP2016\\_17\\_comparison.pdf](https://www.isaps.org/wp-content/uploads/2018/10/ISAP2016_17_comparison.pdf)  
5. Breast reconstruction, 2014 - <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5807774/>  
6. <https://www.plasticsurgery.org/documents/News/Statistics/2018/plastic-surgery-statistics-full-report-2018.pdf>  
<https://www.fda.gov/medical-devices/letters-health-care-providers/breast-implant-associated-anaplastic-large-cell-lymphoma-bia-alcl-letter-health-care-providers>


## CollPlant's 3D bioprinted breast implants



Breast scaffold printing



Loading ECM components +  
autologous fat cells



Implantation and  
vascularization



Implant replacement by  
newly formed tissue





---

## **NASDAQ (CLGN) listed ADR since Jan. 2018**

Market Cap of ~ \$16M\*

---

## **45 employees**

- Strong R&D team
- Fully integrated
- Production team with eight years track record

*\* As of August 30, 2019*



## Planned 12-month milestones

- **Medical aesthetics**

- Sign collaboration agreement with strategic partner
- Photocurable dermal filler animal study

- **3D Bioprinting**

- Expand collaborations with key players
- Breast implants animal study





## CollPlant investment highlights



**Only commercially viable technology** currently available that can produce truly human collagen



**Multi-billion dollar market:** innovative rhCollagen products initially aimed at 3D bioprinting and medical aesthetics



**Broadly applicable technology:** Ideal building block/scaffolding molecule for regenerative medicine



**Strategic agreement with United Therapeutics (UTHR)** for 3D bioprinting of lungs and other life saving organs



**Clinically validated technology**



**Proven management team**

**Thank you**



**CollPlant**  
Biotechnologies

Pioneering  
Regenerative  
Medicine



### **CollPlant Biotechnologies Closes on \$5.5 Million Financing**

#### **Includes \$3.5M from group of U.S. accredited investors with deep expertise in 3D printing**

**Rehovot, Israel, September 9, 2019, CollPlant (NASDAQ:CLGN)**(the “Company”), a regenerative medicine company, announced it has closed on a total of \$5.5 million in convertible loans. A group of U.S. accredited investors with deep experience in the 3D printing industry purchased \$3.5 million of the convertible loans, and the Company’s largest shareholder, Ami Sagi, purchased \$2.0 million of the convertible loans, through a non-brokered private placement.

The convertible loans totaling \$5.5 million automatically convert into the Company’s American Depositary Shares (ADSs) at a conversion price of \$4.00 per ADS following approval of the transaction by CollPlant’s shareholders. Mr. Sagi and the U.S. investors will also receive three-year warrants to purchase up to an aggregate of 1,625,000 ADSs exercisable at an exercise price of \$4.00 per ADS, subject to the satisfaction of certain closing conditions.

An additional \$1.0 million investment will be made by Ami Sagi following the execution of a license and/or a co-development agreement between CollPlant and a strategic business partner, if such were to occur.

For more information on the transaction, please see the Company’s Report on Form 6-K filed with the Securities and Exchange Commission on September 3, 2019.

The securities described above were offered and sold in a private placement under Regulation S and Section 4(a)(2) of the Securities Act of 1933, as amended and Regulation D promulgated thereunder, and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein. There shall not be any offer, solicitation of an offer to buy, or sale of securities in any state or jurisdiction in which such an offering, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

#### **About CollPlant**

CollPlant is a regenerative medicine company focused on 3D bioprinting of tissues and organs, medical aesthetics. Our products are based on our rhCollagen (recombinant human collagen) that is produced with CollPlant’s proprietary plant based genetic engineering technology.

Our products address indications for the diverse fields of organ and tissue repair, and are ushering in a new era in regenerative medicine. Our flagship rhCollagen BioInk product line is ideal for 3D bioprinting of tissues and organs. In October 2018, we entered into a licensing agreement with United Therapeutics, whereby United Therapeutics is using CollPlant’s BioInks in the manufacture of 3D bioprinted lungs for transplant in humans.

For more information about CollPlant, visit <http://www.collplant.com>

---

## Safe Harbor Statements

This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant's objectives plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that CollPlant intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause CollPlant's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company's history of significant losses, its ability to continue as a going concern, and its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all; the Company's expectations regarding the timing and cost of commencing clinical trials with respect to tissues and organs which are based on its rhCollagen based BioInk, dermal fillers for aesthetics, VergenixSTR, and VergenixFG; the Company's ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen based BioInk, dermal fillers for aesthetics, VergenixSTR, and VergenixFG including but not limited to acceptance of an application for marketing authorization, review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based BioInk, dermal fillers for aesthetics, VergenixSTR, and VergenixFG; the Company's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the Company's reliance on third parties to conduct some or all aspects of its product manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company's ability to operate its business without infringing the intellectual property rights of others; the overall global economic environment; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates; projected capital expenditures and liquidity; changes in the Company's strategy; and litigation and regulatory proceedings. More detailed information about the risks and uncertainties affecting CollPlant is contained under the heading "Risk Factors" included in CollPlant's most recent annual report on Form 20-F filed with the SEC, and in other filings that CollPlant has made and may make with the SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect CollPlant's current views with respect to future events, and CollPlant does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact at CollPlant:  
Eran Rotem  
Deputy CEO & CFO  
Tel: + 972-73-2325600  
Email: Eran@collplant.com

---